Compounded Tirzepatide Online in 2026: The Complete Guide

Quick Answer

As of September 26, 2026, compounded tirzepatide is a prescription medication that contains tirzepatide. It is prepared by a state-licensed compounding pharmacy and prescribed by a US-licensed physician for an individual patient. It is not FDA-approved as a final product and is not a generic version of, equivalent to, or interchangeable with any FDA-approved medication. The active pharmaceutical ingredient meets United States Pharmacopeia (USP) standards.

As of September 29, 2026, compounded tirzepatide at Majesta Health (the Performance plan) is $339 your first month, then $439 per month; the first-month price includes the $20 medical consultation fee, and every month includes the physician review, the medication, and shipping. Prices at other US telehealth providers vary with the provider, the dose, and the commitment tier.

What Tirzepatide Actually Does

Tirzepatide is a dual GIP and GLP-1 receptor agonist: the tirzepatide injection prescribing information states that tirzepatide "selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1." Unlike semaglutide, which only activates the GLP-1 receptor, tirzepatide activates both the GIP and GLP-1 receptors at the same time.

What this means in practice:

• Slows gastric emptying. Food stays in your stomach longer, so you feel full sooner and stay full longer.
• Quiets food noise. The constant background hunger and craving signals get dialed down.
• Improves insulin sensitivity. Your body uses insulin more efficiently, which is why tirzepatide also works as a diabetes medication.
• Engages a second receptor pathway. Tirzepatide activates GIP receptors in addition to GLP-1 receptors and may influence appetite-related pathways beyond GLP-1 activation alone. The compounded preparation itself has not been evaluated in clinical trials.

How Compounded Tirzepatide Is Regulated

Compounded tirzepatide is legal in the United States when done correctly: a US-licensed physician writes a patient-specific prescription with a documented clinical reason, a state-licensed 503A compounding pharmacy prepares that patient's medication to USP standards, and all applicable federal and state requirements are met, including restrictions on compounding what is essentially a copy of a commercially available drug. (A separate framework, Section 503B of the same law, covers FDA-registered outsourcing facilities, which are not required to work from patient-specific prescriptions.). The finished compounded product is not FDA-approved and is not a generic version of, equivalent to, or interchangeable with any FDA-approved medication. Whether any tirzepatide treatment is appropriate for you, and in which form, is your physician's clinical decision.

2026 Pricing

*Compounded tirzepatide at Majesta Health (prices as of September 29, 2026):*

• Performance plan: $339 your first month, then $439 per month (physician review, medication, and shipping; the first month includes the $20 medical consultation fee)

Other telehealth providers price compounded tirzepatide in different structures, and their prices change often, so this page does not quote them. How several providers publish their prices, each with its source and the date it was read, is compared in compounded GLP-1 prices compared.

*With insurance:*

Most commercial insurance plans require prior authorization for tirzepatide for weight loss. Many decline coverage unless the patient has type 2 diabetes, where the diabetes-indicated brand product is often covered, or specific obesity comorbidities. Compounded tirzepatide is almost never covered. HSA and FSA cards are accepted by most legitimate telehealth platforms.

What About Clinical Evidence?

No clinical trial has evaluated compounded tirzepatide itself. There are no published efficacy figures for the compounded preparation, and it should not be assumed to be equally safe or effective as any FDA-approved medication. What that means in practice: your prescribing physician decides your prescription and sets realistic expectations based on your medical history and how you respond, and follow-up visits are where progress is actually measured. Weight management outcomes also depend heavily on nutrition, activity, and consistency, not the prescription alone. Individual results vary.

Safety Profile

A physician will counsel you on the side effects known for tirzepatide as an ingredient. The compounded preparation is not FDA-approved as a final product and should not be assumed to behave identically to any studied product.

*Common:*

• Nausea
• Diarrhea
• Decreased appetite
• Vomiting
• Constipation
• Fatigue
• Injection site reactions

Tell your physician about any side effect. The prescribing clinician decides whether to change your prescription; the schedule is on the pharmacy label and set by the prescriber.

*Serious but rare (require physician screening):*

• Pancreatitis
• Gallbladder problems (gallstones, cholecystitis)
• Acute kidney injury from severe dehydration secondary to vomiting or diarrhea
• Diabetic retinopathy worsening in patients with pre-existing diabetic eye disease
• FDA boxed warning about thyroid C-cell tumors in rodents. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

A legitimate physician reviews your medical history, current medications, thyroid history, and pancreatitis history before prescribing. This is the safety step that should never be skipped, whether you choose compounded or brand-name.

Who Should Consider Tirzepatide

Tirzepatide may be the right choice if:

• Your physician finds, from your BMI and your weight-related health conditions, that treatment is medically appropriate for you
• You tried semaglutide and want to discuss another option with your physician
• You have type 2 diabetes (tirzepatide also improves glycemic control)
• You and your physician want to weigh the published clinical data for the FDA-approved dual-agonist products, which describe those products rather than compounded preparations
• You can pay for a cash-pay compounded program out of pocket (at Majesta Health, $339 your first month, then $439 per month), or you have insurance coverage for an FDA-approved tirzepatide medication, which may be a better option to discuss with your physician

Tirzepatide may not be the right choice if:

• You have a personal or family history of medullary thyroid carcinoma or MEN2
• You have a history of pancreatitis
• You are pregnant, trying to conceive, or breastfeeding
• You have severe gastroparesis
• Cost is the primary barrier and a lower-priced option, such as compounded semaglutide injection (at Majesta Health, $179 your first month, then $299 per month), makes more financial sense for your goals

How to Get Compounded Tirzepatide Online Safely

The legitimate path has five steps:

1. Real medical questionnaire. A US-licensed telehealth provider collects your medical history, BMI, current medications, and screening data.
2. Physician review. A licensed physician licensed in your state reviews your file, screens for contraindications (thyroid history, pancreatitis history, kidney function, drug interactions), and decides whether tirzepatide is medically appropriate.
3. Prescription. If appropriate, the physician writes a valid prescription; what it contains is the prescribing clinician's decision, and the schedule is on the pharmacy label.
4. State-licensed compounding pharmacy. Your prescription is sent to a state-licensed 503A compounding pharmacy, which prepares the medication for you as an individual patient under section 503A of the federal Food, Drug, and Cosmetic Act and state pharmacy law.
5. Discreet delivery. Your medication ships in plain packaging, temperature-controlled if needed, signature required.

Ongoing care matters. Questions about side effects and your prescription come up during treatment. Pick a provider that includes ongoing physician messaging in the price, not as a paid add-on.

Red Flags (Avoid These Sources)

A price that looks too good usually means the provider is cutting one of the legitimate steps above. Watch for:

• Sellers offering tirzepatide as "research peptides" or "not for human consumption"
• Online marketplaces or social-media sellers offering tirzepatide without a prescription
• Offshore pharmacies shipping directly to US patients without a US physician prescription
• Telehealth platforms with no named medical director, no published clinical review process, and no clinician licensing transparency
• Anyone promising specific weight loss results, fake before-and-after photos, or testimonials that look manufactured
• A price that seems too good to be true, with no explanation of who prescribes, which licensed pharmacy prepares the medication, and what the monthly amount includes
• Sellers who do not disclose that compounded preparations are not FDA-approved as final products

None of these are safe paths. They also create real legal risk for the buyer in addition to product quality risk.

How Compounded Tirzepatide Compares to Semaglutide

Tirzepatide and semaglutide are different molecules with different mechanisms, and which one fits you is a clinical decision. Your physician weighs your history, tolerability, and goals rather than headline averages.

Trade-offs:

• Cost. At Majesta Health, as of September 29, 2026, the compounded tirzepatide plan is $339 your first month, then $439 per month, and the compounded semaglutide plan is $179 your first month, then $299 per month.
• Side effect burden. Your physician reviews how you tolerate treatment and decides any change to your prescription.
• Insurance coverage. FDA-approved weight-management medications are sometimes covered with prior authorization; if your insurance covers one, that may be a better option to discuss with your physician. Compounded preparations are almost never covered.

Which medication fits a given patient is a clinical decision. A clinician weighs prior response, tolerability, medical history, preferences, and available FDA-approved options; no treatment or sequence is right for every patient.

The Bottom Line

Compounded tirzepatide is a legal, US-licensed-physician path to dual GIP and GLP-1 weight loss treatment in 2026, priced as one bundled monthly cash amount. It contains tirzepatide, and the compounded preparation is not FDA-approved as a final product and is not a generic version of, or interchangeable with, any brand medication. It is prepared at state-licensed compounding pharmacies under a real physician's prescription and is dispensed only to patients with a valid medical evaluation.

At Majesta Health it is $339 your first month, then $439 per month, as of September 29, 2026, with the $20 medical consultation fee included in the first month; prices at other providers vary. Whether any treatment is appropriate for you is a clinical decision made by a licensed physician, not a pricing decision.

The most important variable is not whether you pick compounded or brand-name. It is whether the prescribing physician and the dispensing pharmacy are legitimate. A licensed physician who reviews your medical history and a named, state-licensed compounding pharmacy are the safety standards that matter most.

If you are considering tirzepatide, start the medical assessment at /quiz. A US-licensed physician reviews your information and decides whether treatment is appropriate; no prescription is guaranteed.

What the primary sources say

• DailyMed, U.S. National Library of Medicine, tirzepatide injection prescribing information, section 12.1 Mechanism of Action (accessed September 26, 2026): "Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1."
• MedlinePlus Drug Information, Tirzepatide Injection (accessed September 26, 2026): "Tirzepatide injection caused thyroid tumors in rats. It is not known if this medication increases the risk of tumors in humans. Tell your doctor if you or anyone in your family has or ever had thyroid cancer or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) syndrome"
• U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers (accessed September 26, 2026): "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."
• Legal Information Institute, Cornell Law School, 21 U.S. Code § 353a, Pharmacy compounding (accessed September 26, 2026): "a licensed pharmacist in a State licensed pharmacy or a Federal facility, or (B) a licensed physician, on the prescription order for such individual patient made by a licensed physician or other licensed practitioner authorized by State law to prescribe drugs"
• U.S. Food and Drug Administration, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (accessed September 26, 2026): "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list."

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider. Compounded medications are not FDA-approved as final products. Majesta Health prices are as of September 29, 2026 and are subject to change. Individual results may vary.

Related cost and comparison guides

• Compounded tirzepatide cost in 2026